MLYS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MLYS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Mineralys Therapeutics does not have enough data to calculate Degree of Operating Leverage.
The historical data trend for Mineralys Therapeutics's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mineralys Therapeutics Annual Data | |||||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||
Degree of Operating Leverage | - | - | - | - | - |
Mineralys Therapeutics Quarterly Data | |||||||||||||||
Dec20 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Degree of Operating Leverage | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Mineralys Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Degree of Operating Leverage falls into.
Mineralys Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:
Degree of Operating Leverage | = | % Change in EBIT** | / | % Change in Revenue |
= | ( -201.488 (Mar. 2025) / -105.081 (Mar. 2024) - 1 ) | / | ( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 ) | |
= | 0.9175 | / | ||
= | N/A*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Mineralys Therapeutics (NAS:MLYS) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Thank you for viewing the detailed overview of Mineralys Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
David Malcom Rodman | officer: Chief Medical Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
Jon Congleton | director, officer: Chief Executive Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
Adam Scott Levy | officer: CFO, Chief Bus. Off. and Secy. | C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Srinivas Akkaraju | director, 10 percent owner | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Catalys Pacific Fund, Lp | 10 percent owner | 301 9-19 HACHIYAMA, SHIBUYA, TOKYO M0 150-0035 |
Glenn Sblendorio | director | 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
Daphne Karydas | director | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Hbm Healthcare Investments (cayman) Ltd. | 10 percent owner | GOVERNORS SQUARE, 23 LIME TREE BAY AVE.,, PO BOX 30852, GRAND CAYMAN E9 KY1-1204 |
Olivier Litzka | director | C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087 |
Takeshi Takahashi | director | C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087 |
Brian Taylor Slingsby | director, 10 percent owner | C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER RD, STE. F200, RADNOR PA 19087 |
Ra Capital Nexus Fund Iii, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Samsara Biocapital, L.p. | 10 percent owner | 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
Alexander Asam | director | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
From GuruFocus
By Marketwired • 05-20-2025
By Marketwired • 03-18-2025
By Marketwired • 03-10-2025
By GlobeNewswire • 04-23-2025
By GuruFocus News • 02-13-2025
By GuruFocus News • 05-13-2025
By Marketwired • 03-25-2025
By GuruFocus News • 05-14-2025
By GuruFocus News • 03-25-2025
By GuruFocus News • 02-12-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.